<!doctype html>
<html lang="ko">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, user-scalable=no, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0">
  <meta http-equiv="X-UA-Compatible" content="ie=edge">
  <title>보령제약</title>
  <link rel="stylesheet" href="css/base.css">
  <link rel="stylesheet" href="css/style.css">
  <script src="js/include.js" defer></script>
</head>
<body>
<div class="container">
  <div class="wrap kr-view">
    <div data-include="/include/header.html" class="header"></div>

    <article>
      <section class="ceo" data-nm="2">
        <h2 mov>CEO Letter.</h2>
        <div class="select-box" mov data-delay="1">
          <ul>
            <li><a data-list="1"><i class="kr">장두현 대표이사</i><i class="en">CEO Daniel Chang</i></a></li>
            <li><a onclick="goCeo('jk')" data-list="2"><i class="kr">김정균 대표이사</i><i class="en">CEO Jay Kim</i></a></li>
          </ul>
        </div>
        <div class="ceo-letter">
          <p class="tit kr" mov data-delay="2">2022 CEO Letter <span class="nm">by 장두현</span></p>
          <p class="tit en" mov data-delay="2"><img src="img/mo/ceo-sign2.png" alt="CEO Daniel Chang"></p>
          <div class="txt kr">
            <p mov data-delay="2">(수정 중) 1957년 종로5가 보령약국을 시작으로 1963년 제약업을 시작한 보령제약은 ‘인류의 건강과 공존 공영’ 위한 노력을 계속해 왔습니다.</p>
            <p mov data-delay="2">대한민국 성장의 시절, 질병으로 인한 고통을 조금이나마 덜겠다는 보령의 노력은 용각산, 겔포스로 실현되고, 세계에서 인정받는 신약을 개발하겠다는 꿈은 고혈압 신약 카나브로 현실화 되었습니다. 카나브는 대한민국 신약의 성공모델로서 글로벌 시장에 진출하며 만성질환 환자들의 고통을 덜어주고 있습니다.</p>
            <p mov data-delay="2">의료기술의 발전과 개인 건강관리에 대한 관심이 높아지면서 건강한 삶 그리고 삶의 질 향상에 대한 관심도 더욱 높아 지고 있습니다. 하지만, 이와 반대로 현재 우리가 알지 못하는 신종바이러스의 출현 등 건강한 삶에 대한 도전도 거세지고 있습니다.</p>
            <p mov data-delay="2">건강한 삶에 대한 요구와 도전에 저희 보령제약이 답하는 길은 더 큰 꿈을 꾸는 것이라고 생각합니다. 우리가 제약업을 영위하는 것도, 또 우리가 신약을 개발하는 이유는 하나입니다. 경제적 성과를 넘어, 인류 모두가 질병의 고통에서 벗어나 더욱 건강하고 행복한 삶을 누리고 싶은 꿈을 실현시키기 위해서입니다.</p>
            <p mov data-delay="2">이를 위해, 보령은 끊임없이 도전하고 진화해 나갈 것입니다. 자체 R&D와 오픈이노베이션을 통해 혁신적인 신약 개발은 물론 지속적으로 미래성장동력을 발굴∙강화할 것입니다. 또한, 세계 최고 수준의 생산설비를 바탕으로 더 안전하고 우수한 약을 공급하며 생명의 소중함을 지키는 제약업의 본질을 충실히 실현하는 한편, 책임 있는 기업 시민으로써 더불어 사는 ‘공존공영’의 사회를 만들기 위해 사회공헌 활동, 환경경영, 윤리경영에도 앞장설 것입니다.</p>
            <p mov data-delay="2">무엇보다 개인의 ‘질병 치료(CURE)’를 넘어 ‘삶의 질 향상(CARE)’을 위해서 우리는 헬스케어산업 뿐 만 아니라, 모든 산업, 세계 그 어떤 기업과도 손을 잡고 가장 과학적인 답을 제공할 것입니다.</p>
            <p mov data-delay="2">인류 모두가 ‘자신을 행복하게 하는 일’을 ‘더 많이, 더 오랫동안 할 수 있는 삶’을 누릴 수 있도록 ‘Life Time Care Company BORYUNG’의 도전은 계속될 것입니다.</p>
            <p mov data-delay="2">보령제약의 끊임없는 도전과 혁신에 많은 관심과 응원 부탁드립니다.</p>
            <p mov data-delay="2">감사합니다.</p>
            <p class="date" mov data-delay="2">2022.03.25</p>
            <p class="sign" mov data-delay="2">㈜ 보령 대표이사 장두현</p>
          </div>
          <div class="txt en">
            <p mov data-delay="2">Boryung delivered remarkable financial results in 2021, in spite of the unfavorable operating environment amid the COVID-19 pandemic. We achieved record-high earnings last year, with revenue rising 10%YoY to KRW595.3bn and operating profit soaring 25%YoY to KRW50.2bn.</p>
            <p mov data-delay="2">Our Kanarb line-up, which celebrated its 10th anniversary last year, posted KRW110bn in sales, demonstrating the superb quality and commercial competitiveness of domestic new drugs. Our oncology business, which boasts a dominant standing in Korea, grew 17%YoY and topped KRW100bn in sales. Furthermore, we acquired the entire rights of original drugs that retain solid brand loyalty even after patent expiry. The strategy of acquiring legacy brands led to the assetization of Zyprexa, a major medicine for schizophrenia.</p>
            <p mov data-delay="2">We also achieved sales growth in co-promoted items, which is a remarkable feat. For instance, Trulicity, the No. 1 injection drug for diabetes in Korea that hit the domestic market in 2016, exhibited a CAGR of staggering 43% during 2017-2021 and posted KRW46.9bn in sales last year. Our OTC drugs also stood out. Two steady sellers, Gelfos and Yonggaksan, are still achieving sales growth. Gelfos, Korea’s first drug export item to China, extended its distribution networks across that country last year in collaboration with Sinopharm International of China. As for Yonggaksan Cool, B2C sales more than doubled YoY and led overall market growth even as the respiratory disease treatment market shrank last year.</p>
            <p mov data-delay="2">Above all, our sustained profitable growth is impressive. Boryung has displayed sales growth for 16 straight years since 2005 while breaking previous highs for three consecutive years since 2019.</p>
            <p mov data-delay="2">We plan to fortify our strategies for the pharmaceutical business in order to establish the groundwork for the mid/long-term growth of new Boryung. We aim to maximize profitability over the mid-term by strengthening the quality of our products. This year, we will focus on reinforcing the profitability of our products and bolstering the portfolio of new products in order to lay the firm foundation for growth.</p>
            <p mov data-delay="2">First, our Kanarb family drugs will lead robust sales growth based on new combination drug launches and various treatment options to achieve KRW200bn in sales by 2026. To this end, an evergreening strategy will be implemented for the Kanarb brand so that it will not lose competitiveness even after patent expiry. In addition, Boryung plans to raise market share further by more than doubling clinical study budgets for Kanarb and other prescription drugs (Rx) and executing marketing activities based on clinical evidence.</p>
            <p mov data-delay="2">Second, Boryung is determined to position itself as a dominant player in the oncology market by: 1) extending the portfolio of oncology drugs, Boryung’s future growth driver, through new partnerships (e.g., additional biosimilar co-promotions) and 2) expanding the portfolio of anticancer supportive care products. In addition, Boryung plans to raise our share of the hematologic malignancy market through the establishment of HEMA sales group in 2021, the only hematologic malignancy sales company in Korea. Furthermore, we will accelerate the development of BR2002, a medicine for Non-Hodgkin’s lymphoma that showed remarkable efficacy through complete remission at clinical studies in 2021.</p>
            <p mov data-delay="2">Third, we aim to raise the sales ratio of our own products up to 70% by 2026 in order to secure the highest profitability in the industry. For this, we will strive to continuously acquire original drugs through LBA strategy and engage more actively with the central nervous system (CNS) drug business on the back of Zyprexa which was assetized last year. Moreover, we will focus on developing generics for major drugs and establishing the pipelines of incrementally modified drugs (IMDs) for diabetes, hyperlipidemia and urinary disease.</p>
            <p mov data-delay="2">Lastly, we will establish solid presence in overseas markets this year while expanding the Chinese market share of Gelfos through strengthened supply networks across that country last year.</p>
            <p mov data-delay="2">We are certain 2022 will see Boryung lay the groundwork for a quantum leap ahead. All of Boryung’s members, including myself, are committed to pushing for relentless innovation and embracing challenges. We call for your unwavering support to help us dream bigger and set our sights on higher grounds.</p>
            <p mov data-delay="2">Thank you.</p>
            <p class="sign" mov data-delay="2">Boryung CEO<br> Daniel Chang</p>
          </div>
        </div>
      </section>
    </article>
    <footer data-include="/include/footer.html"></footer>
  </div>
</div>
<script src="js/polyfill.js"></script>
<script src="js/header.js"></script>
<script src="js/index.js"></script>
<script>
  function goCeo(v) {
    let langValue = localStorage.getItem('lang')
    location.href = 'ceo-'+v+'.html?' + langValue;
  }
  temp = location.href.split('?');
  history.replaceState(temp, '', 'ceo-dan.html');

</script>
</body>
</html>